Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.32 -1.9%	$14.68	$9.57 ▼ $30.41	$2.12B	0.96	1.54 million shs	2.78 million shs
BHC Bausch Health Cos	$6.17 -0.2%	$4.98	$3.96 ▼ $9.85	$2.29B	0.28	2.63 million shs	2.80 million shs
NAMS NewAmsterdam Pharma	$17.96 -1.3%	$18.51	$14.06 ▼ $27.29	$2.02B	-0.03	699,446 shs	1.01 million shs
VERV Verve Therapeutics	$11.06 -0.5%	$5.49	$2.86 ▼ $11.41	$985.92M	1.67	2.37 million shs	7.72 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.92%	-2.67%	+0.07%	+3.51%	-35.02%
BHC Bausch Health Cos	-0.37%	+2.58%	+37.26%	-13.89%	-4.64%
NAMS NewAmsterdam Pharma	-1.32%	-11.13%	-2.97%	-24.76%	+4.97%
VERV Verve Therapeutics	-0.54%	+79.55%	+161.47%	+99.28%	+116.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5175 of 5 stars	3.4	1.0	3.4	2.4	2.5	0.0
BHC Bausch Health Cos	3.6654 of 5 stars	1.9	2.0	4.0	3.8	3.3	0.6
NAMS NewAmsterdam Pharma	2.9977 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0
VERV Verve Therapeutics	2.9273 of 5 stars	4.2	1.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	185.34% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	20.21% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	138.80% Upside
VERV Verve Therapeutics	2.38	Hold	$14.75	33.36% Upside

Current Analyst Ratings Breakdown

Latest VERV, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	595.97	N/A	N/A	$1.54 per share	9.95
BHC Bausch Health Cos	$9.63B	0.24	$7.71 per share	0.80	($0.89) per share	-6.93
NAMS NewAmsterdam Pharma	$45.56M	44.26	N/A	N/A	$8.20 per share	2.19
VERV Verve Therapeutics	$32.33M	30.49	N/A	N/A	$5.83 per share	1.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.02	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.32	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest VERV, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
NAMS NewAmsterdam Pharma	20.84%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

VERV, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

Research Analysts Offer Predictions for VERV Q2 Earnings

June 21 at 1:17 AM | americanbankingnews.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20 at 1:07 PM | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20 at 9:15 AM | globenewswire.com

Lifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 20 at 1:58 AM | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC Wainwright

June 20 at 1:58 AM | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial Group

June 20 at 1:58 AM | americanbankingnews.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19 at 7:06 AM | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19 at 2:26 AM | insidenova.com

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19 at 2:26 AM | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19 at 1:19 AM | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18 at 11:28 PM | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18 at 10:35 AM | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18 at 8:05 AM | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18 at 8:05 AM | marketbeat.com

Verve Therapeutics' (VERV) "Hold" Rating Reiterated at Jefferies Financial Group

June 18 at 8:05 AM | marketbeat.com

Lock In The 81.5% Run - Initiating Verve With A Sell

June 18 at 7:36 AM | seekingalpha.com

Verve Therapeutics (NASDAQ:VERV) Sets New 12-Month High - Here's Why

June 18 at 5:05 AM | marketbeat.com

Canaccord Genuity Group Reiterates Hold Rating for Verve Therapeutics (NASDAQ:VERV)

June 18 at 2:27 AM | americanbankingnews.com

Verve Therapeutics Target of Unusually High Options Trading (NASDAQ:VERV)

June 18 at 1:12 AM | americanbankingnews.com

These Stocks Are Moving the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

June 17, 2025 | msn.com

Eli Lilly to Acquire Verve Therapeutics for $1 Billion

June 17, 2025 | pharmexec.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERV, NAMS, BHC, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.32 -0.30 (-1.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.35 +0.03 (+0.20%)

As of 06/20/2025 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.17 -0.01 (-0.16%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$6.13 -0.04 (-0.65%)

As of 06/20/2025 07:51 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$17.96 -0.24 (-1.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$18.15 +0.19 (+1.06%)

As of 06/20/2025 07:39 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Verve Therapeutics NASDAQ:VERV

$11.06 -0.06 (-0.54%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$11.03 -0.03 (-0.27%)

As of 06/20/2025 07:58 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time